RFG Bristol Wealth Advisors LLC Buys Shares of 12,690 Medline $MDLN

RFG Bristol Wealth Advisors LLC bought a new stake in shares of Medline (NASDAQ:MDLN) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 12,690 shares of the company’s stock, valued at approximately $565,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of MDLN. Carlyle Group Inc. bought a new position in Medline in the 4th quarter valued at $9,042,728,000. H&F Corporate Investors X Ltd. bought a new stake in shares of Medline during the fourth quarter worth $4,179,591,000. Vanguard Group Inc. purchased a new stake in shares of Medline during the fourth quarter valued at $793,278,000. Morgan Stanley bought a new position in shares of Medline in the fourth quarter worth about $636,807,000. Finally, Capital Research Global Investors bought a new position in shares of Medline in the fourth quarter worth about $620,937,000.

Medline Trading Up 2.0%

NASDAQ MDLN opened at $39.44 on Thursday. Medline has a one year low of $32.81 and a one year high of $50.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.41. The company has a market capitalization of $51.81 billion and a price-to-earnings ratio of 123.25. The company’s 50-day simple moving average is $37.80 and its two-hundred day simple moving average is $42.08.

Medline (NASDAQ:MDLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.04. The business had revenue of $7.35 billion during the quarter. Medline’s revenue was up 10.7% on a year-over-year basis. Equities analysts forecast that Medline will post 1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MDLN. Deutsche Bank Aktiengesellschaft set a $42.00 price objective on shares of Medline in a report on Thursday, May 7th. Sanford C. Bernstein reduced their target price on shares of Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Citigroup decreased their price target on shares of Medline from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. BTIG Research reiterated a “buy” rating and issued a $55.00 price target on shares of Medline in a report on Thursday, May 7th. Finally, Barclays dropped their price objective on Medline from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $50.54.

Insiders Place Their Bets

In related news, insider Jessi L. Corcoran bought 5,000 shares of the stock in a transaction on Friday, June 5th. The stock was bought at an average price of $34.15 per share, for a total transaction of $170,750.00. Following the completion of the acquisition, the insider directly owned 5,000 shares in the company, valued at approximately $170,750. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Douglas P. Golwas sold 100,000 shares of the stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total value of $3,677,000.00. Following the sale, the insider directly owned 23,899 shares in the company, valued at $878,766.23. This trade represents a 80.71% decrease in their position. The SEC filing for this sale provides additional information. 0.81% of the stock is owned by corporate insiders.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.